Discover how negative pressure wound therapy with instillation is easier than ever to help promote healing for complex wounds.
We incorporated clinicians' feedback to create the new Veraflo Cleanse Choice Complete Dressing Kit. The kit includes fewer pieces, is easier to use and is more patient friendly than previous kits.
The Smart Instill Feature uses sophisticated software that automates many of the Veraflo Therapy steps and delivers an easier and less time-consuming interaction when initiating installation therapy.
Delivers topical wound solutions that dwell in the wound to help dilute and solubilize infectious material³
Removes solubilized wound debris and infectious materials, under negative pressure to help lower bioburden⁴
Promotes granulation tissue formation and perfusion to prepare the wound for closure⁵
A systematic review of comparative studies and meta-analysis evaluated the performance of Veraflo Therapy versus control in 13 studies and 720 patients in various wound types. Results of the analysis revealed Veraflo Therapy delivered significant advantage over standard of care, including traditional NPWT.
(9.88 days vs 21.8 days, p=0.02)
(7.88 days vs 14.36 days, p=0.003)
(p=0.01)
(1.77 debridements vs 2.69, p=0.008)
Odds were 4.4 times greater (p=0.003)
Based upon the meta-analysis by Allen Gabriel, MD et al. an economic model⁶ was developed to compare the cost of using Veraflo Therapy to traditional wound care options including V.A.C.® Therapy. Despite higher therapy cost of Veraflo Therapy, the reduction in therapy time and required OR visits resulted in a potential savings of 50%, or up to $33,337 per patient.
NOTE: The model uses select study data to provide an illustration of estimates of costs for use of Veraflo Therapy or Standard of Care (Control). This model is an illustration and not a guarantee of actual individual costs, savings, outcomes or results. The facility is advised to use this model as an illustration only to assist in an overall assessment of products and pricing
Wounds may be susceptible to contamination or the development of bioburden – key contributors to complications like infection, inflammation, and delayed healing. 3M™ Veraflo™ Therapy combines vacuum assisted drainage with automated topical wound solution distribution to consistently cleanse and remove wound debris helping to reduce bioburden.
Following a boating injury, a 26-year-old female received transfemoral amputation that resulted in soft tissue defect measuring approximately 90x45cm². Antibiotics were administered throughout the patient treatment period. With patient critical condition and debridement no longer an option, Veraflo Therapy with V.A.C. Veraflo Cleanse Choice Dressing was initiated. Dwell time: 5 minutes NPWT time: 2 hours at -150mmHg Solution: 100mL Dankin's Solution.
Patient data and photos courtesy of Brandon Hill, RN, CWCN, FACCWS; Ochsner Louisiana State University Health Shreveport, Shreveport, LA
NOTE: As with any case study, the results and outcomes should not be interpreted as a guarantee or warranty of similar results. Individual results may vary depending on the patient’s circumstances and condition.
An error has occurred while submitting. Please try again later...
Your form was submitted successfully. A 3M representative will reach out to you soon.
From product demos, purchase inquiries to technical training, our team is here to help.
1. Bjarnsholt T, Eberlein T, Malone M, Schultz G. Management of wound biofilm made easy. London: Wounds International 2017; 8(2).
2. A fact a day – biofilms and wound care. Wound Source. 2018. Available at: https://pages.woundsource.com/woundsource-practice-accelerator-biofilms-and-wound-care/.
3. Teot L, Boissiere F, Fluieraru S. Novel foam dressing using negative pressure wound therapy with instillation to remove thick exudate, Int Wound J. 2017 Oct;14(5):842-848.
4. Brinkert D, Mazen A, Naud M, Maire N, Trial C, Teot L. Negative pressure wound therapy with saline instillation: 131 patient case series. Int Wound J. 2013 Dec;10 Suppl1:56-60.
5. Gupta S, Gabriel A, Lantis J, Teot L. Clinical recommendations and practical guide for negative pressure wound therapy with instillation. Int Wound J. 2016 Apr; 13(2):159-174.
6. Gabriel, Allen MD, FACS; Camardo, Mark MS; O’Rorke, Erin BS; Gold, Rebecca BS; Kim, Paul J.DPM, MS, FACFAS Effects of Negative-Pressure Wound Therapy With Instillation versus Standard of Care in Multiple Wound Types: Systematic Literature Review and Meta-Analysis, Plastic and Reconstructive Surgery: January 2021 - Volume 147 - Issue1S-1 - p 68S-76S doi:10.1097/PRS.0000000000007614.
7. Camardo, Mark. “Veraflo Meta-Analysis Standardized and Non-Standardized Means.”, 3M Internal Report, San Antonio,Texas, 2020.
Wolcott RD, Rumbaugh KP, James G, et al. Biofilm maturity studies indicate sharp debridement opens a time-dependent therapeutic window. J Wound Care. 2010; 19 (8):320-328.
8. Costerton JW, Stewart PS, Greenberg EP. Bacterial Biofilms: A Common Cause of Persistent Infection. Science. 1999; 284 (5418):1318-1322.
9. Davies DG, Geesey GG. Regulation of the Alginate Biosynthesis Gene algC in Pseudomonas aeruginosa during Biofilm Development in Continuous Culture. Appl Environ Microbiol. 1995; 61(3):860-867.
10. Cicmanec F, Holder IA. Growth of Pseudomonas aeruginosa in Normal and Burned Skin Extract: Role of Extracellular Proteases. Infect Immun. 1979; 25(2):477-483.
11. Harrison-Balestra C, Cazzaniga BS, Davis SC, et al. A Wound-Isolated Pseudomonas aeruginosa Grows a Biofilm In Vitro Within 10 Hours and Is Visualized by Light Microscopy. Dermatol Surg. 2003: 29(6):631-635.
12. Schaber JA, Triffo WJ, Suh SJ, et al. Pseudomonas aeruginosa Forms Biofilms in Acute Infection Independent of Cell-to-Cell Signaling. Infect Immun. 2007; 75 (8):3715-3721.
13. Wolcott RD, Rumbaugh KP, James G, et al. Biofilm maturity studies indicate sharp debridement opens a time-dependent therapeutic window. J Wound Care. 2010; 19 (8):320-328.
14. Kim PJ, Attinger CE, Constantine T, et al. Negative pressure wound therapy with instillation: international consensus guidelines update. Int Wound J. 2020 Feb;17(1):174-186